These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8049300)

  • 1. Musings on the struggle--Part V: Beginning the N2/TIL protocol.
    Anderson WF
    Hum Gene Ther; 1994 Apr; 5(4):427-8. PubMed ID: 8049300
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetically marking human cells--results of the first clinical gene transfer studies.
    Cai Q; Rubin JT; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF/TIL human gene therapy clinical protocol.
    Hum Gene Ther; 1990; 1(4):441-80. PubMed ID: 2078586
    [No Abstract]   [Full Text] [Related]  

  • 4. The N2-TIL human gene transfer clinical protocol.
    Hum Gene Ther; 1990; 1(1):73-92. PubMed ID: 2081189
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombinant interleukin-2 alone, or with recombinant interleukin-2 and recombinant alpha interferon.
    Hum Gene Ther; 1992 Aug; 3(4):411-30. PubMed ID: 1326336
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene therapy of cancer.
    Rosenberg SA
    Important Adv Oncol; 1992; ():17-38. PubMed ID: 1582673
    [No Abstract]   [Full Text] [Related]  

  • 7. Musings on the struggle--Part II: The N2-TIL protocol.
    Anderson WF
    Hum Gene Ther; 1993 Jun; 4(3):237-8. PubMed ID: 8338871
    [No Abstract]   [Full Text] [Related]  

  • 8. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
    Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
    Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes.
    Hum Gene Ther; 1992 Apr; 3(2):167-77. PubMed ID: 1391037
    [No Abstract]   [Full Text] [Related]  

  • 12. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C; Zhao Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 15. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor.
    Donia M; Larsen SM; Met O; Svane IM
    Cytotherapy; 2014 Aug; 16(8):1117-20. PubMed ID: 24831841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.
    Lindenberg MA; Retèl VP; van den Berg JH; Geukes Foppen MH; Haanen JB; van Harten WH
    J Immunother; 2018; 41(9):413-425. PubMed ID: 30300260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
    Han B; Jia Y; Zhou M
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Embryonic stem cell research moves slowly through appeals courts, cancer trials.
    Jenks S
    J Natl Cancer Inst; 2011 Jul; 103(14):1078-9. PubMed ID: 21737694
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission.
    Brenner M; Krance R; Heslop HE; Santana V; Ihle J; Ribeiro R; Roberts WM; Mahmoud H; Boyett J; Moen RC
    Hum Gene Ther; 1994 Apr; 5(4):481-99. PubMed ID: 8049305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.